^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    LiquidMARK™ Bile Duct test

    Company:
    Lucence
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    LiquidMARK™ Bile Duct, powered by AmpliMARK™ next generation sequencing technology, is an ultrasensitive next-generation sequencing blood test that identifies relevant gene mutations – including the fibroblast growth factor receptor 2 (FGFR2) fusion gene that Innovent’s Pemazyre® is effective against. Patients with FGFR2 fusion identified through the LiquidMARK™ Bile Duct test will be eligible to receive Pemazyre® as second-line treatment.
    Cancer:
    Biliary Tract Cancer
    Gene:
    FGFR2 (Fibroblast growth factor receptor 2)
    Drug:
    Pemazyre (pemigatinib)
    Method:
    Next-Generation Sequencing (NGS)